Evolving The Retinal Landscape

Iveric Bio is committed to developing innovative therapies that address unmet needs of patients suffering from the progressive symptoms of common and rare retinal diseases.

Innovations for Tomorrow's Retinal Disease Patients

With a diverse portfolio of therapeutic candidates at different stages of development, our pipeline is focused on bringing innovative treatments for retinal diseases to those who need them most.

For details on our pipeline, including our lead product candidate, avacincaptad pegol, click on the programs listed below.

Therapeutics Pipeline

  • Research
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • FDA Review
Avacincaptad pegol Geographic atrophy associated with various stages of disease
Avacincaptad pegol Autosomal recessive Stargardt disease
IC-500: HtrA1 inhibitor Geographic atrophy

AAV Gene Therapy Pipeline†

  • Research
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • FDA Review
mini-CEP290: LCA10 Leber congenital amaurosis type 10
mini-ABCA4: STGD1* Autosomal recessive Stargardt disease
mini-USH2A* Usher syndrome type 2A

†In December 2022, Iveric Bio assigned the rights to its licenses to IC-100 (RHO-adRP) and IC-200 (BEST1-related IRDs) to Opus Genetics
*Iveric Bio has an option to exclusively in-license intellectual property from these sponsored research programs

Discover More About Our Ongoing Clinical Studies
Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More